Arbutus Biopharma Corporation

ABUS

CA03879J1003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-14 pm EDT			5-day change	1st Jan Change
3.240 ^USD	+2.21%		+3.18%	-0.92%

Jun. 25	Arbutus Biopharma Corporation and Qilu Pharmaceutical Co., Ltd. Announce Termination Agreement	CI
Jun. 25	Arbutus Biopharma Reacquires Rights to Imdusiran in China	MT

Genevant Sciences And Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Published on 03/03/2025 at 09:48

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Arbutus Biopharma Corporation

Arbutus Biopharma Corporation and Qilu Pharmaceutical Co., Ltd. Announce Termination Agreement	Jun. 25	CI
Arbutus Biopharma Reacquires Rights to Imdusiran in China	Jun. 25	MT
Arbutus Launches a New Scientific Advisory Board	Jun. 25	CI
Arbutus and Qilu Pharmaceutica Concludes the Strategic Partnership for Development, Manufacturing and Commercialization of Imdusiran	Jun. 25	CI
Arbutus Biopharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 14	CI
Arbutus Biopharma Corporation Presents Clinical Trial Data from Its Two HBV Assets, Imdusiran and AB-101, At the European Association for the Study of the Liver Congress 2025	May. 07	CI
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 27	CI
Arbutus Biopharma Corporation Announces CFO Changes, Effective from March 28 2025	Mar. 27	CI
Arbutus Biopharma Corporation to Reduce Workforce by 57% and Exits Warminster Headquarters	Mar. 27	CI
Arbutus Biopharma Corporation Announces Executive Changes	Mar. 27	CI
Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement	Mar. 03	MT
Genevant Sciences And Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna	Mar. 03	RE
Roivant Sciences Announces Resignation and Replacement of Directors at Arbutus Biopharma	Feb. 25	CI
Arbutus Biopharma Names Lindsay Androski CEO, Overhauls Board	Feb. 25	MT
Arbutus Biopharma Corporation Announces Management Changes	Feb. 25	CI
Arbutus Biopharma Corporation Announces CEO Changes	Feb. 25	CI
Arbutus Biopharma Corporation - Special Call	Dec. 03
Chardan Research Adjusts Price Target on Arbutus Biopharma to $5 From $4.50, Maintains Buy Rating	Nov. 20	MT
Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results	Nov. 15	MT
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B	Nov. 15	CI
Arbutus? Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon	Nov. 15	CI
Arbutus Biopharma Corporation, Q3 2024 Earnings Call, Nov 06, 2024	Nov. 06
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q3 Revenue $1.3M	Nov. 06	MT
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q3 Revenue $1.3M	Nov. 06	MT
Arbutus Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 06	CI

Chart Arbutus Biopharma Corporation

Duration

Period

ABUS: Dynamic Chart

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patientsâ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

Employees

Sector

Biotechnology & Medical Research

Calendar

Jul. 30 - Q2 2025 Earnings Release (Projected)

More about the company